EVALUATION OF ATROMID S (CLOFIBRATE) IN HYPERLIPIDEMIC STATES: INTERIM REPORT

Atromid S has been evaluated in an uncontrolled trial on a clinical material of hyperlipidemic states, comprising 354 individuals, including an unusually high number of cases of essential hypercholesterolemic xanthomatosis. Follow-up periods varied between 1/2 and 41/2 years. Side-effects, reasons for withdrawal, persistency of lipid-lowering effects, rates of mortality and attacks of myocardial infarctions have been discussed. A significant and persistent lipid-lowering effect was seen in all varieties. Although moderate, this was also apparent in severe hypercholesterolemic xanthomatosis. Mortality and infarction rates were low—as was also the frequency of side-effects. No serious side-effects were seen. The drug is considered to merit a considerable extension and prolongation of the study.